[Adobe Stock]
The big Big Pharma names you couldn’t ignore
Despite biopharma’s 2023 layoffs and challenges, innovation won your clicks last year with over 130,000 of them on our Pharma 50 report alone. But while giants dominated, your clicks showed disruptive tech wasn’t far behind. The next-most popular article was a roundup of 100 trailblazing cell and gene therapy companies with more than 80,000 views. Other hits included companies putting AI in drug discovery and development, and the ever-popular biotech startup watch – proof that solutions, not just statistics, attract attention. Rounding out the top five was a roundup of biotech job cuts and openings.
2023 biopharma innovation in the spotlight on Linkedin
But over on LinkedIn, innovation was also a driver of interest. Topics on women’s health, such as
Organon doubling down on women’s health, novel approaches to mental illness at Gate Neuro, and head-to-head comparisons of blockbuster weight loss drugs sparked the most reactions.
Other stories that fared best on the social media platform included CinCor’s stock surge after the AstraZeneca buyout announcement, the first episode of “AI Meets Life Sci,” and Gate Neurosciences’ novel approaches in depression treatment dominating engagements.
In 2023, LinkedIn engagement with Drug Discovery & Development content surged, with a 41.6% increase in impressions. Overall engagement was up 39.8%.
AI and techbio on display
My own LinkedIn profile witnessed a surge in engagement overall, jumping 1,640.3% over the past year. Some of the best-performing articles there include an exploration of Recursion’s Phenom-Beta partnership with NVIDIA (11,475 impressions). The partnership centers around democratizing access to phenomics (the large-scale study of phenotypes) by converting images of human cells into mathematical biology models, which has the potential to accelerate drug discovery and personalized medicine.
An article on the techbio landscape was next-most popular with 9,987 impressions followed by an examination of Virginia’s life sciences boom with 8,803 impressions.
The data and engagement metrics across LinkedIn and Google Analytics tell one clear story: you aren’t just looking for trends in biopharma, you want to create them. My own experience with LinkedIn shows that giving industry leaders a platform to share their ideas can resonate widely. Expect 2024’s DD&D coverage to amplify these voices more than ever. But we want to know: Do you see an unheard story the industry needs to consider? Share, so we can ensure we aren’t missing a story that deserves the spotlight. If something comes to mind, hit me up on LinkedIn.